Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX727 and Dasatinib in Newly Diagnosed CML-CP
NCT05007873Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2021
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of inqovi in chronic myeloid leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2021; status: active, not recruiting.
02
Drugs
inqovi
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT05007873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05007873.